BridgeBio Pharma
Stock Forecast, Prediction & Price Target
BridgeBio Pharma (BBIO) stock Price Target by analysts
$45.5
Potential downside: -8.54%
BridgeBio Pharma price prediction
What is BridgeBio Pharma stock analysts` prediction?
BridgeBio Pharma stock forecast: Based on 2 Wall Street analysts` predicted price targets for BridgeBio Pharma in the last 3 months, the avarage price target is $45.5, with a high forecast of $NaN. The average price target represents a -8.54% change from the last price of $49.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
BridgeBio Pharma stock Price Target by analysts
Full breakdown of analysts given BridgeBio Pharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Lebowitz Citigroup | 0% 0/1 | 11 months ago | $45 -9.54% downside | $24.17 | StreetInsider | Previous targets (0) |
Mani Foroohar Leerink Partners | 0% 0/1 | 11 months ago | $46 -7.53% downside | $26.34 | TheFly | Previous targets (0) |
Biren Amin Piper Sandler | 0% 0/1 | about 1 year ago | $46 -7.53% downside | $28.78 | StreetInsider | Previous targets (0) |
Salim Syed Mizuho Securities | 0% 0/1 | about 1 year ago | $53 6.53% upside | $29.92 | StreetInsider | Previous targets (0) |
Danielle Brill Raymond James | 0% 0/1 | over 1 year ago | $46 -7.53% downside | $22.65 | StreetInsider | Previous targets (0) |
Kostas Biliouris BMO Capital | 0% 0/1 | over 1 year ago | $37 -25.62% downside | $26.93 | StreetInsider | Previous targets (0) |
Tiago Fauth Wells Fargo | 0% 0/1 | over 1 year ago | $58 16.58% upside | $27.13 | StreetInsider | Previous targets (0) |
Paul Choi Goldman Sachs | 0% 0/1 | over 1 year ago | $50 0.50% upside | $27.61 | StreetInsider | Previous targets (0) |
Eliana Merle UBS | 0% 0/1 | over 1 year ago | $47 -5.52% downside | $27.94 | StreetInsider | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | over 1 year ago | $43 -13.56% downside | $30.09 | StreetInsider | Previous targets (0) |
Cory Kasimov Evercore ISI | 0% 0/1 | over 1 year ago | $50 0.50% upside | $28.5 | StreetInsider | Previous targets (0) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $19 -61.80% downside | $9.58 | Benzinga | N/A |
Dane Leone Raymond James | 100% 1/1 | over 3 years ago | $17 -65.82% downside | $10.76 | Pulse 2.0 | Previous targets (0) |
BridgeBio Pharma Financial Estimates
BridgeBio Pharma Revenue Estimates
BridgeBio Pharma EBITDA Estimates
BridgeBio Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $69.71M N/A | $77.64M 11.37% | $9.30M -88.01% | Avg: $249.54M Low: $120.12M High: $520.35M avg. 2582.38% | Avg: $553.90M Low: $337.30M High: $1.09B avg. 121.96% | Avg: $1.14B Low: $695.10M High: $2.25B avg. 106.07% | Avg: $1.88B Low: $1.14B High: $3.71B avg. 64.77% |
Net Income
% change YoY
| $-639.29M N/A | $-493.96M 22.73% | $-643.20M -30.21% | Avg: $-526.38M Low: $-616.97M High: $-78.13M avg. 18.16% | Avg: $-306.03M Low: $-564.88M High: $39.06M avg. 41.85% | Avg: $-29.95M Low: $-67.90M High: $-14.72M avg. 90.21% | Avg: $490.81M Low: $241.31M High: $1.11B avg. 1738.58% |
EBITDA
% change YoY
| $-539.67M N/A | $-353.67M 34.46% | $-565.46M -59.88% | Avg: $-249.54M Low: $-520.35M High: $-120.12M avg. 55.86% | Avg: $-553.90M Low: $-1.09B High: $-337.30M avg. -121.96% | Avg: $-1.14B Low: $-2.25B High: $-695.10M avg. -106.07% | Avg: $-1.88B Low: $-3.71B High: $-1.14B avg. -64.77% |
EPS
% change YoY
| -$4.43 N/A | -$3.35 24.37% | -$3.95 -17.91% | Avg: -$2.93 Low: -$3.79 High: -$0.48 avg. 25.90% | Avg: -$1.85 Low: -$3.47 High: $0.24 avg. 36.96% | Avg: -$0.18 Low: -$0.42 High: -$0.09 avg. 90.02% | Avg: $3.02 Low: $1.48 High: $6.84 avg. 1738.58% |
Operating Expenses
% change YoY
| $646.34M N/A | $546.08M -15.51% | $614.22M 12.47% | Avg: $2.03B Low: $979.66M High: $4.24B avg. 231.31% | Avg: $4.51B Low: $2.75B High: $8.91B avg. 121.96% | Avg: $9.30B Low: $5.66B High: $18.38B avg. 106.07% | Avg: $15.33B Low: $9.34B High: $30.28B avg. 64.77% |
FAQ
What is BridgeBio Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 472.20% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -616.97M, average is -526.38M and high is -78.13M.
What is BridgeBio Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 718.80% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $120.12M, average is $249.54M and high is $520.35M.
What is BridgeBio Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 472.86% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$3.79, average is -$2.93 and high is $-0.48.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering BridgeBio Pharma stock. The most successful analyst is David Lebowitz.